These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32123158)

  • 1. Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.
    Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Malandrakis P; Eleutherakis-Papaiakovou E; Papatheodorou A; Kanellias N; Migkou M; Fotiou D; Dialoupi I; Roussou M; Kokkali NA; Kastritis E; Dimopoulos MA
    Blood Cancer J; 2020 Mar; 10(3):25. PubMed ID: 32123158
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.
    Tageja N; Korde N; Kazandjian D; Panch S; Manasanch E; Bhutani M; Kwok M; Mailankody S; Yuan C; Stetler-Stevenson M; Leitman SF; Sportes C; Landgren O
    Bone Marrow Transplant; 2018 Nov; 53(11):1445-1449. PubMed ID: 29728700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
    Dimopoulos M; Wang M; Maisnar V; Minarik J; Bensinger W; Mateos MV; Obreja M; Blaedel J; Moreau P
    J Hematol Oncol; 2018 Apr; 11(1):49. PubMed ID: 29615082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
    Siegel DS; Dimopoulos MA; Ludwig H; Facon T; Goldschmidt H; Jakubowiak A; San-Miguel J; Obreja M; Blaedel J; Stewart AK
    J Clin Oncol; 2018 Mar; 36(8):728-734. PubMed ID: 29341834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis.
    Costa BA; Costa TA; Pak K; Patel A; Felix N; Mouhieddine TH; Richter J
    Am J Hematol; 2024 Jul; 99(7):1411-1414. PubMed ID: 38606993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
    Roussel M; Lauwers-Cances V; Wuilleme S; Belhadj K; Manier S; Garderet L; Escoffre-Barbe M; Mariette C; Benboubker L; Caillot D; Sonntag C; Touzeau C; Dupuis J; Moreau P; Leleu X; Facon T; Hébraud B; Corre J; Attal M
    Blood; 2021 Jul; 138(2):113-121. PubMed ID: 33827114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
    Jakubowiak A; Usmani SZ; Krishnan A; Lonial S; Comenzo RL; Wang J; de Boer C; Deraedt W; Weiss BM; Schecter JM; Chari A
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):701-710. PubMed ID: 34274290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
    Leypoldt LB; Besemer B; Asemissen AM; Hänel M; Blau IW; Görner M; Ko YD; Reinhardt HC; Staib P; Mann C; Lutz R; Munder M; Graeven U; Peceny R; Salwender H; Jauch A; Zago M; Benner A; Tichy D; Bokemeyer C; Goldschmidt H; Weisel KC
    Leukemia; 2022 Mar; 36(3):885-888. PubMed ID: 34732857
    [No Abstract]   [Full Text] [Related]  

  • 9. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
    Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall A; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
    J Clin Oncol; 2022 Sep; 40(25):2901-2912. PubMed ID: 34898239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].
    Fuchida SI; Shimura K; Taminishi-Katsuragawa Y; Matsui-Maegawa S; Okano A; Hatsuse M; Murakami S; Shimazaki C
    Rinsho Ketsueki; 2019; 60(10):1468-1470. PubMed ID: 31695009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
    Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
    Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
    Derman BA; Cooperrider J; Rosenblatt J; Avigan DE; Rampurwala M; Barnidge D; Major A; Karrison T; Jiang K; Ramsland A; Kubicki T; Jakubowiak AJ
    Blood Cancer J; 2024 May; 14(1):87. PubMed ID: 38811560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
    Derman BA; Stefka AT; Jiang K; McIver A; Kubicki T; Jasielec JK; Jakubowiak AJ
    Blood Cancer J; 2021 Feb; 11(2):19. PubMed ID: 33563912
    [No Abstract]   [Full Text] [Related]  

  • 16. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
    Leypoldt LB; Tichy D; Besemer B; Hänel M; Raab MS; Mann C; Munder M; Reinhardt HC; Nogai A; Görner M; Ko YD; de Wit M; Salwender H; Scheid C; Graeven U; Peceny R; Staib P; Dieing A; Einsele H; Jauch A; Hundemer M; Zago M; Požek E; Benner A; Bokemeyer C; Goldschmidt H; Weisel KC
    J Clin Oncol; 2024 Jan; 42(1):26-37. PubMed ID: 37753960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
    Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S
    Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
    Forsberg PA; Rossi AC; Boyer A; Pearse RN; Pekle KA; Jayabalan D; Lakritz S; Flicker K; Ribadeneyra D; Liotta B; Ely S; Boussi L; Allan JN; Coleman M; Niesvizky R; Mark TM
    Am J Hematol; 2021 Dec; 96(12):1554-1562. PubMed ID: 34424561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Carfilzomib, lenalidomide, and dexamethasone therapy for refractory and relapsed multiple myeloma: a single-center study of 29 patients].
    Okazuka K; Ishida T; Sato K; Miyazaki K; Yoshiki Y; Abe Y; Tsukada N; Suzuki K
    Rinsho Ketsueki; 2018; 59(6):698-700. PubMed ID: 29973446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.
    Campioni M; Agirrezabal I; Hajek R; Minarik J; Pour L; Spicka I; Gonzalez-McQuire S; Jandova P; Maisnar V
    Eur J Health Econ; 2020 Mar; 21(2):219-233. PubMed ID: 31673898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.